Expanded Access to REGN4461 for Patients With Diseases Associated With Deficient Leptin Signaling
Trial statusAvailable
Trial phaseNot listed
Trial typeExpanded Access
Biological sexAll
AgeNot listed
SponsorRegeneron Pharmaceuticals
About this trial
Provide Expanded Access to REGN4461 for patients with diseases associated with deficient leptin signaling.
Eligibility criteria
Qualifiers
None
Disqualifiers
None
Trial design
Treatments tested in this trial
- REGN4461
Treatment groups
No treatment groups listed
Locations
Sponsors and collaborators
Source ClinicalTrials.gov